Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SABBOBCATon Jan 27, 2023 3:48pm
138 Views
Post# 35250980

RE:RE:RE:New job posting

RE:RE:RE:New job posting Again, if preclinical wasn't sound, you would scrap the program and go back to the drawing board. To me, this reads as if there was lack of governance relating to the trial. Whether that be lack of proper protocols or poor communication or both, who knows. But this does indicate they want to move something forward.
SPCEO1 wrote: That reads to me like an indictment of Christian. Perhaps on further review, the great preclinical work may have had some flaws? Or, it could be they found protocols were not being followed in the phase 1a and 1b leading to the pause due to weird results. There clearly is a big gap between the preclinical results and the still unknown phase 1a and 1b results, so I am sure they are trying to figure that out.
scarlet1967 wrote:
"Audit activities to ensure that Theratechnologies pre-clinical and clinical studies are conducted according to protocols and that any deviation is documented and assessed"
THTX isn't involved with any preclinical studies but Sort1!!




<< Previous
Bullboard Posts
Next >>